Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell LungCancer. Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lungcancer (NSCLC). Methods In this double-blind, phase 3 trial
Tafinlar & Mekinist in combo for Non-Small Cell LungCancer – Details Tafinlar & Mekinist in combo for Non-Small Cell LungCancer – Details | CADTH.ca Find the information you need Tafinlar & Mekinist in combo for Non-Small Cell LungCancer – Details Tafinlar & Mekinist in combo for Non-Small Cell LungCancer – Details Project Number pCODR 10106 Brand Name Tafinlar & Mekinist in combo Generic Name Dabrafenib & Trametinib in combo Strength Dabrafenib: 50mg and 75mg capsules; Trametinib: 0.5mg (...) and 2.0mg tablet Tumour Type Lung Indication Non-Small Cell LungCancer Funding Request In combination for the treatment of patients with advanced non-small cell lungcancer (NSCLC) with a BRAF V600 mutation and who have been previously treated with chemotherapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Submitter Novartis Pharmaceuticals Canada Inc. Submission Date March 31, 2017 Submission Type New Indication Prioritization Requested
UNBS5162 inhibits the proliferation of human A549 nonâ€smallâ€cell lungcancer cells by promoting apoptosis ORIGINAL ARTICLE UNBS5162 inhibits the proliferation of human A549 non-small-cell lungcancer cells by promoting apoptosis Cuicui Liu 1 , Jiaqiang Xing 2 & Yujun Gao 3 1 Department of Oncology, Linyi City People’s Hospital, Linyi, China 2 Department of Thoracic Surgery, Linyi Cancer Hospital, Linyi, China 3 Department of Thoracic Surgery, Af?liated Hospital of Shandong Academy (...) of Medical Sciences, Jinan, China Keywords Apoptosis; non-small-cell lungcancer; PI3K pathway; proliferation; UNBS5162. Correspondence Jiaqiang Xing, Department of Thoracic Surgery, Linyi Cancer Hospital of Shandong Province, Linyi 276000, China. Tel: +86 539 812 1803 Fax: +86 539 812 1803 Email: firstname.lastname@example.org Received: 29 August 2017; Accepted: 26 September 2017. doi: 10.1111/1759-7714.12546 Thoracic Cancer 9 (2018) 105–111 Abstract Background: Lungcancer is one of the most frequently
Cyclophilin A promotes nonâ€small cell lungcancermetastasis via p38 MAPK ORIGINAL ARTICLE Cyclophilin A promotes non-small cell lungcancermetastasis via p38 MAPK Yinan Guo 1 , Mei Jiang 1 , Xiaoting Zhao 1 , Meng Gu 1 ,Ziyu Wang 1 , Shaofa Xu 2 & Wentao Yue 1 1 Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China 2 Department of Thoracic Surgery, Beijing Chest Hospital (...) , Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China Keywords Cyclophilin A (CypA); metastasis; non-small cell lungcancer (NSCLC); p38 MAPK. Correspondence Shaofa Xu, Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, 9#, Beiguan Street, Tongzhou, Beijing 101149, China. Tel: +86 10 8950 9181 Fax: +86 10 8050 7349 Email: email@example.com Wentao Yue
Plateletâ€toâ€lymphocyte ratio predicts the prognosis of patients with nonâ€small cell lungcancer treated with surgery and postoperative adjuvant chemotherapy 29105365 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Platelet-to-lymphocyte ratio predicts the prognosis of patients with non-small cell lungcancer treated with surgery and postoperative adjuvant chemotherapy. 112-119 10.1111/1759-7714.12547 Markers of preoperative tumor immunity, such as platelet (...) -to-lymphocyte ratio (PLR), have been reported to be prognostic factors for patients with various cancers. However, the relationship between PLR and the prognosis of non-small cell lungcancer (NSCLC) patients treated with surgery and adjuvant chemotherapy as a multidisciplinary treatment is unknown. We enrolled 327 NSCLC patients treated surgically with or without adjuvant chemotherapy (78 and 249 patients, respectively) at our hospital from 2008 to 2012. Patients had no preoperative hematological disease
CRTC2 promotes nonâ€small cell lungcancer A549 migration and invasion in vitro 29105369 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer CRTC2 promotes non-small cell lungcancer A549 migration and invasion in vitro. 136-141 10.1111/1759-7714.12550 CRTC2 is highly expressed in lungcancer and contributes to lungcancer pathogenesis; however, whether CRTC2 promotes lungcancermetastasis remains unknown. In the present study, we investigated the role of CRTC2 in lung (...) cancermetastasis in vitro. CRTC2 stable knockdown of lungcancer cell A549 was generated with small hairpin RNA and confirmed by quantitative reverse transcription-PCR and Western blot. Wound healing and invasion transwell assays were performed to explore migration and invasion activity, and Western blot was conducted to detect the expression of related proteins. Suppression of CRTC2 significantly inhibited A549 cell migration and invasion in vitro. Mechanistic studies showed that knockdown of CRTC2
Different EGFR gene mutations in two patients with synchronous multiple lungcancers: A case report 29090842 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Different EGFR gene mutations in two patients with synchronous multiple lungcancers: A case report. 189-192 10.1111/1759-7714.12554 Routine clinical and pathological evaluations to determine the relationship between different lesions are often not completely conclusive. Interestingly, detailed genetic analysis (...) of tumor samples may provide important additional information and identify second primary lungcancers. In the present study, we report cases of two synchronous lung adenocarcinomas composed of two distinct pathological subtypes with different EGFR gene mutations: a homozygous deletion in exon 19 of the papillary adenocarcinoma subtype and a point mutation of L858R in exon 21 of the tubular adenocarcinoma. The present report highlights the clinical importance of molecular cancer biomarkers to guide
Enhanced recovery after surgery using uniportal videoâ€assisted thoracic surgery for lungcancer: A preliminary study 29087621 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Enhanced recovery after surgery using uniportal video-assisted thoracic surgery for lungcancer: A preliminary study. 83-87 10.1111/1759-7714.12541 This study investigated the clinical efficiency of enhanced recovery after surgery (ERAS) using uniportal video-assisted thoracoscopic surgery (...) for lungcancer. The clinical data of 83 patients with early-stage non-small cell lungcancer (NSCLC) at the First Affiliated Hospital of Soochow University from January 2016 to February 2017 were retrospectively analyzed. ERAS was applied to 38 patients (ERAS group), while 45 patients received conventional surgical treatment (control group). The operative duration, number of lymph nodes retrieved, blood loss, visual analogue scale (VAS), postoperative duration of chest tube placement, length
Detection of circulating tumor cells using oHSV1â€hTERTâ€GFP in lungcancer 29068150 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Detection of circulating tumor cells using oHSV1-hTERT-GFP in lungcancer. 44-50 10.1111/1759-7714.12526 This study was conducted to evaluate the clinical utility of the oHSV1-hTERT-GFP circulating tumor cell (CTC) detection method in the peripheral blood of patients with lungcancer by comparing its sensitivity to the CellSearch CTC (...) detection method. The oHSV1-hTERT-GFP and CellSearch CTC detection methods were compared using peripheral blood samples of patients pathologically diagnosed with lungcancer. A total of 240 patients with lungcancer were recruited, including 89 patients who were newly diagnosed and 151 patients who had previously received treatment. Sixty-six newly diagnosed patients were evaluated using both methods. The CTC detection rates were 71.2% and 33.3% using the oHSV1-hTERT-GFP and CellSearch methods
Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced nonâ€small cell lungcancer 29067769 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lungcancer. 99-104 10.1111/1759-7714.12545 Recent studies have revealed a reduction in the skeletal muscle area (...) in patients with advanced non-small cell lungcancer (NSCLC) after chemotherapy. EGFR and ALK tyrosine kinase inhibitor (TKI)-based therapies are less cytotoxic than chemotherapy, but differences in skeletal muscle mass between patients receiving EGFR and ALK TKI therapies and patients receiving cytotoxic chemotherapy have not yet been reported. Data of pathologically proven NSCLC patients were reviewed, and chest computed tomography and/or positron emission tomography-computed tomography images obtained
Remarkable response of nivolumabâ€refractory lungcancer to salvage chemotherapy 29063735 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Remarkable response of nivolumab-refractory lungcancer to salvage chemotherapy. 175-180 10.1111/1759-7714.12543 Promising outcomes of salvage chemotherapy after nivolumab therapy have been reported; however, little is known about the detailed clinical and immunologic features in lungcancer patients in whom nivolumab (...) is unsuccessful. We report two cases of nivolumab-refractory lungcancer, in which chemotherapy resulted in rapid regression of the lungcancer. Upon initial diagnosis, the biopsy specimens showed PD-ligand 1 (PD-L1)-expressing cancer cells, accompanied by tumor-infiltrating lymphocytes with a favorable CD8/CD4 ratio. Immunosuppressive regulatory T cells and cells positive for TIM-3 were also observed. Physicians should take caution in treating lungcancer patients after progression on nivolumab. Further
Pitfalls in diagnosis with the use of circulating tumorâ€derived epidermal growth factor receptor mutations in lungcancer harboring pretreatment T790M 29063709 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lungcancer harboring pretreatment T790M. 171-174 10.1111/1759-7714.12538 The circulating tumor DNA (ctDNA) assay has recently been approved (...) for the selection of EGFR-tyrosine kinase inhibitors as first-line treatment in lungcancer. However, it remains to be determined whether this assay can detect all complex EGFR mutations within a single tumor. We report a case of an elderly woman with stage IV lung adenocarcinoma, in which EGFR mutation assays detected L858R and pretreatment T790M from a tissue biopsy. In contrast, the circulating tumor DNA assay detected L858R, but not pretreatment T790M in the plasma, regardless of the fact that similar
GM-CSF promotes a supportive adipose and lung microenvironment in metastatic breast cancer 29142902 2018 11 13 2331-4737 4 9-10 2017 Sep Oncoscience Oncoscience GM-CSF promotes a supportive adipose and lung microenvironment in metastatic breast cancer. 126-127 10.18632/oncoscience.371 Reggiani Francesca F Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy. Bertolini Francesco F Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy. eng (...) Editorial 2017 10 23 United States Oncoscience 101636666 2331-4737 Cancer Res. 2012 Jan 1;72(1):325-34 22052460 Cancer Res. 2009 Mar 1;69(5):2133-40 19223554 BMC Cancer. 2013 Nov 09;13:535 24209831 Cancer Res. 2013 Oct 1;73(19):5880-91 23918796 Nat Cell Biol. 2017 Aug;19(8):974-987 28737771 Breast Cancer Res. 2013;15(5):R102 24176089 Cancer Res. 2000 Jun 15;60(12):3239-46 10866317 Adipose tissue GM-CSF breast cancer neutrophils CONFLICTS OF INTEREST The authors declare no conflicts of interest. 2017 10
Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecanâ€related toxicities in patients with lungcancer 29052349 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lungcancer. 51-58 10.1111/1759-7714.12535 The objective of this study was to evaluate the effects of gene polymorphisms, including UGT1A1*7, *27, and *29, on the safety of irinotecan (...) therapy. The eligibility criteria were: lungcancer patients scheduled to undergo irinotecan therapy, aged ≥ 20 years, with a performance status of 0-2. Thirty-one patients were enrolled and their blood was collected and used to examine the frequency of UGT1A1*6, *7, *27, *28, and *29 polymorphisms and the concentrations of irinotecan, SN-38, and SN-38G after irinotecan therapy. The patients' characteristics were as follows: male/female 25/6, median age 71 years (range 55-84), stage IIB/IIIA/IIIB/IV 2
Risk factors of lymph node metastasis in patients with nonâ€small cell lungcancer â‰¤ 2â€‰cm in size: A monocentric populationâ€based analysis 29034994 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Risk factors of lymph node metastasis in patients with non-small cell lungcancer ≤ 2 cm in size: A monocentric population-based analysis. 3-9 10.1111/1759-7714.12490 This study was designed to determine the risk factors of lymph node metastasis in non-small cell lung (...) cancer (NSCLC) patients with tumors ≤ 2 cm, using the Shanghai Chest Hospital LungCancer Database. Five hundred and eighteen patients with NSCLC ≤ 2 cm were included in this study, and were classified into lymph node-positive and lymph node-negative groups. Univariate and multivariate logistic regression analyses were performed to select the independent risk factors for lymph node metastasis in NSCLC patients. No evidence of metastasis was found in tumors ≤ 1 cm, all positive results were in tumors